Considering the limitations and undesirable side effects observed in cancer therapy with platinum derivatives, many efforts have been made with the aim of obtaining new drugs more effective and less toxic, able to promote the hydrolytic cleavage or oxidative DNA chain other subcellular structures critical. Until now, some copper complexes have been developed and showed excellent in vitro activity against a variety of experimental tumors. Thus, knowledge on the cytotoxicity and selectivity compounds of copper (II) containing bridging hydroxide is therefore of importance in the search for new drugs for cancer treatment. Moreover, because it is a physiological metal, its compounds are usually less toxic than platinum derivatives, thus reducing unwanted side effects and thereby enabling the increase of chemotherapeutic arsenal available for treatment of the disease. In this context, were developed in this work binucleantes two ligands derived from isoniazid (INH). One of these ligands, the non-symmetrical N-isonicotinoil-2-hydroxy-3-{[(2-hydroxybenzyl) (2-piridilmetil) amino]-methyl}-5-hydrazone methylbenzaldehyde, is new. But the other, the symmetrical ligand N, N -diisonicotinoyl-2-hydroxy-5-methylisophthalaldehyde dihydrazone, was originally synthesized by a team led by Chen in 1992. From these ligands, four new binuclear complexes of Cu (II) bridges containing exogenous hydroxo and acetate, all of which contain a hydroxo-bridge type between the metals were synthesized and characterized by various instrumental techniques of analysis. In addition, theoretical calculations were made with the aim of helping the proposals regarding the structure of the compounds. Future works will be performed to investigate the biological activity of these complexes.